-Down to Earth State blames poor financial condition for the move The Bihar government has defended its recent move to lower its minimum wage rate offered to unskilled labourers, saying the state is in poor financial condition. Bihar has lowered its wage rate offered under the Mahatma Gandhi National Rural Employment Guarantee Act (MGNREGA) from Rs 144 to Rs 135, while the state minimum wage is Rs 168. This is despite the...
More »SEARCH RESULT
Total Matching Records found : 2557
Calling big pharma’s bluff -Dwijen Rangnekar
-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...
More »SC orders Sterlite to pay Rs. 100 crore as relief
-PTI The Supreme Court on Tuesday asked Sterlite Industries, a subsidiary of U.K.-based Vedanta Group, to pay Rs. 100 crore as compensation for polluting environment through its copper smelting plant in Tamil Nadu but refused to direct its closure. A bench headed by Justice A.K. Patnaik said that the environment has been polluted for a long time due to the discharge from the plant of the multinational company and it has...
More »Supreme Court imposes Rs 100 crore fine on Sterlite Industries
-Reuters India's top court imposed a fine of Rs 100 crore ($18.40 million) on Sterlite Industries for polluting environment through its copper smelting plant in Tamil Nadu. The case is unrelated to a separate order that has shut the Tuticorin plant, India's largest, since last week following complaints of a gas leak. Despite the fine, the Supreme Court overruled an earlier order from the Madras High Court to shut down the plant over...
More »A just order
-The Hindu The Supreme Court Order rejecting a plea to grant patent protection for Glivec, a cancer-fighting drug from Novartis, is a landmark. It will greatly strengthen the quest for access to affordable medicines in India. The decision affirms the idea that a patent regime loses its social relevance when a drug is priced beyond the reach of the vast majority of a country's people. That pharmaceutical companies employ high pricing...
More »
